Change to SMC outwith remit criteria
SMC has introduced a more streamlined and consistent approach for biosimilar, generic and hybrid medicines.
From 1 March 2024, all generic, biosimilar and hybrid medicines are outwith SMC remit, irrespective of SMC advice for the originator medicine.
‘Accepted’ and ‘accepted restricted’ SMC advice will still apply to the originator medicine following the availability of generics or biosimilars; any associated Patient Access Scheme (PAS) will remain available for the originator medicine.
However, ‘not recommended’ advice for the originator medicine will no longer be applicable once generic or biosimilar medicines become available. All SMC advice will remain on the SMC website.
Where there is a clinical need, health boards may make decisions about the continued application of ‘not recommended’ SMC advice, for example, inclusion in local / regional formularies.
Please refer to the ‘Guidance to companies on medicines outwith SMC remit’ at https://www.scottishmedicines.org.uk/making-a-submission/
About us
- Who we are
- Horizon scanning
- Public involvement
- Policies & publications
- Minutes
- Meetings
- Register for a meeting
- ILAP
-
Latest update
- HIS website survey
- Speeding up access to new medicines in Scotland: abbreviated process
- International Collaboration
- Joint statement: NICE and SMC/HIS collaboration
- NICE draft recommendations published on the use of treatments for COVID-19
- Healthcare Improvement Scotland
- NICE and SMC/HIS collaboration on health technology appraisal of therapeutics for COVID-19
- Her Majesty Queen Elizabeth II
- April 2022 decisions news release
- New access tool launched as part of SMC’s joint work on streamlining patient access to innovative medicines
- December 2021 decisions news release
- November 2021 decisions news release
- March 2023 decisions news release
- SMC publishes a Collaborative Advice Document for treatments for COVID-19
- Public Partner Advert
- Fast Track Resubmission Process
- NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
- SMC publishes an updated Collaborative Advice Document for COVID-19 medicines
- NICE issues final draft guidance on multiple technology appraisal (MTA), ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor– ivacaftor for treating cystic fibrosis.
- Contact us